Quetiapine monotherapy in acute phase for major depressive disorder: A meta-analysis of randomized, placebo-controlled trials

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Maneeton, Narong ^a   Maneeton, Benchalak ^a   Srisurapanont, Manit ^a   Martin, Stephen D ^b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b Brandon Lane Neuropsychiatry Clinic ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; QUETIAPINE;

ARTICLE; CLINICAL ASSESSMENT; COCHRANE LIBRARY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PITTSBURGH SLEEP QUALITY INDEX; PSYCINFO; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REMISSION; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; MONOTHERAPY; SLEEP TIME; SYSTEMATIC REVIEW;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 84866703076     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-160     Document Type: Article

References (50)

1. Waraich P, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatr 2004, 49(2):124-138.
2. Culpepper L. Understanding the burden of depression. J Clin Psychiatr 2011, 72(6):e19.
3. Rush AJ, Wisniewski SR, Zisook S, Fava M, Sung SC, Haley CL, Chan HN, Gilmer WS, Warden D, Nierenberg AA, et al. Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. Psychol Med 2011, 42(6):1-19.
4. Ustün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004, 184:386-392. 10.1192/bjp.184.5.386, 15123501.
5. Bech P, Cialdella P. Citalopram in depression-meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 1992, 6(Suppl 5):45-54.
6. Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 1992, 7(2):91-94.
7. Entsuah AR, Rudolph RL, Chitra R. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a meta-analysis. Psychopharmacol Bull 1995, 31(4):759-766.
8. Mallinckrodt CH, Watkin JG, Liu C, Wohlreich MM, Raskin J. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features. BMC Psychiatr 2005, 5:1.
9. Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Gersons BP, van Strik R, Broekmans AW. Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 2001, 11(2):173-180. 10.1016/S0924-977X(01)00083-9, 11313164.
10. Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002, 325(7371):991. 10.1136/bmj.325.7371.991, 131022, 12411354.
11. Furukawa T, McGuire H, Barbui C. Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev 2003, (3):CD003197.
12. Papakostas GI, Fava M. A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can J Psychiatr 2006, 51(12):783-790.
13. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatr 2001, 62(11):869-877.
14. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001, 178:234-241. 10.1192/bjp.178.3.234, 11230034.
15. Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatr 2010, 11(2 Pt 2):300-307.
16. Papakostas GI, Nelson JC, Kasper S, Moller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2008, 18(2):122-127. 10.1016/j.euroneuro.2007.07.005, 17719752.
17. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373(9665):746-758. 10.1016/S0140-6736(09)60046-5, 19185342.
18. Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatr 2006, 67(Suppl 6):3-8.
19. Montgomery SA. The under-recognized role of dopamine in the treatment of major depressive disorder. Int Clin Psychopharmacol 2008, 23(2):63-69. 10.1097/YIC.0b013e3282f2b3cb, 18301120.
20. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20(5):389-409. 10.2165/00023210-200620050-00004, 16696579.
21. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008, 33(10):2303-2312. 10.1038/sj.npp.1301646, 18059438.
22. Bakken GV, Rudberg I, Molden E, Refsum H, Hermann M. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 2011, 33(2):222-226.
23. Goldstein JM, Nyberg S, Brecher M. Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel. Eur Psychiatr 2008, 23(suppl 2):S202.
24. Altamura AC, Moliterno D, Paletta S, Buoli M, Dell'osso B, Mauri MC, Bareggi SR. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study. Clin Drug Investig 2012, 32(3):213-219. 10.2165/11597330-000000000-00000, 22299714.
25. Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatr 2011, 72(1):75-80.
26. Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol 2012, 27(2):76-90. 10.1097/YIC.0b013e32834e4c56, 22107783.
27. Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs 2012, 26(5):435-460. 10.2165/11203840-000000000-00000, 22519923.
28. Kjelby E, Jorgensen HA, Kroken RA, Loberg EM, Johnsen E. Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiatr 2011, 11:145.
29. Amit BH, Weizman A. Antidepressant treatment for acute bipolar depression: an update. Depress Res Treat 2012, 2012:684725. 3272786, 22319648.
30. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 2010, 27(10):964-976. 10.1002/da.20740, 20734365.
31. Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, Earley W, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2011, 128(1-2):83-94.
32. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009, 14(6):299-313.
33. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Astrom M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatr 2009, 70(4):526-539.
34. Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, Mors O, Elkin A, Williamson RJ, Schmael C, et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 2008, 38(2):289-300.
35. Higgins JPT, Altman DG. Assessing risk of bias in included studies. Cochrane Handbook for SystematicReviews of Interventions. Version 5.1.0 (Updated March 2011) 2011, The Cochrane Collaboration, Higgins JPT, Green S, [http://www.cochrane-handbook.org].
36. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry 2008, 69(E1):8-13.
37. Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ. A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol 2006, 59(4):342-353. 10.1016/j.jclinepi.2005.08.017, 16549255.
38. Sterne JAC, Egger M, Moher D. Addressing Reporting Biases. Cochrane Handbook for SystematicReviews of Interventions. Version 5.1.0 (Updated March 2011) edition 2011, The Cochrane Collaboration, Higgins JPT, Green S, [http://www.cochrane-handbook.org].
39. A multi-center, double-blind, randomized, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate extended-release (Seroquel XR™) as mono-therapy in the treatment of elderly patients with major depressive disorder (SAPPHIRESTUDY). AstraZeneca Clinical Trials http://www.astrazenecaclinicaltrials.com/drug-products/seroquel/?itemId=8543679.
40. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang Y. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatr 2005, 66(8):974-981.
41. Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 2006, 22(9):1825-1837. 10.1185/030079906X132415, 16968586.
42. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits From Antidepressants: Synthesis of 6-Week Patient-Level Outcomes From Double-blind Placebo-Controlled Randomized Trials of Fluoxetine and Venlafaxine. Arch Gen Psychiatry 2012, 69(6):572-579. 10.1001/archgenpsychiatry.2011.2044, 3371295, 22393205.
43. Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008, 178(3):296-305. 2211353, 18227449.
44. Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006, 40(4):337-348. 10.1016/j.jpsychires.2005.08.010, 16271726.
45. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, Kerse N, Macgillivray S. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev 2009, (3):CD007954.
46. Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatr Clin Neurosci 2009, 259(3):172-185.
47. Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG, Kornstein SG. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. J Affect Disord 2006, 94(1-3):183-189.
48. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996, 39(6):411-418. 10.1016/0006-3223(95)00188-3, 8679786.
49. Beasley CM, Nilsson ME, Koke SC, Gonzales JS. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. J Clin Psychiatr 2000, 61(10):722-728.
50. Brecht S, Kajdasz D, Ball S, Thase ME. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder. Int Clin Psychopharmacol 2008, 23(6):317-324. 10.1097/YIC.0b013e328306a987, 18854719.